Exicure

11:00 AM - 11:15 AM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary spherical nucleic acid (SNA™) architecture is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address inflammatory diseases, genetic disorders and oncology. Exicure is based outside of Chicago, IL.
Ticker:
XCUR
Exchange:
Nasdaq
Company Type:
Company Website:
Company HQ State:
Illinois
Company HQ Country:
United States
Year Founded:
2011
Main Therapeutic Focus:
Lead Product in Development:
AST-008 (TLR9 agonist)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided